谢红光(兼职导师)

发布者:基础医学发布时间:2016-03-14浏览次数:351

谢红光,医学博士,药理学教授,南京医科大学博士生导师。1995年于中南大学湘雅医学院获博士学位。1997年获美国默沙东 (MSD) 国际临床药理学奖学金,在范德堡 (Vanderbilt) 大学医学院临床药理学系接受博士后培训后留校继续从事临床药理学研究,曾先后在加州大学旧金山分校 (UCSF) 和美国联邦政府食品与药品管理局 (FDA) 学习与工作。2011年11月回国工作,应聘为南京医科大学药理学教授、博士生导师。现任南京市第一医院中心实验室主任,是江苏省特聘医学专家、江苏省药学会第一届药物基因组学专业委员会委员、江苏省心血管疾病临床医学研究中心之心 血管药物的临床药理学、药物基因组学与个体化治疗的临床和实验研究分中心主任。

主要从事临床药理学、药物代谢与转运、药物基因组学、个体化药物治疗、种族药理学等方面的研究,是我国药物基因组学研究的早期领军学者之一和药物经济学的倡导与实践者。早年参与我国汉族和少数民族人群药物代谢能力差异及其机制的研究,获1999年度湖南省科学技术进步奖一等奖(排名第二)。曾先后主持国家自然科学基金青年基金、面上项目、国家人力资源与社会保障部出国留学回国人员资助项目、江苏省自然科学基金面上项目等多个研究课题,早年作为主创人员之一参与申请和承担国家自然科学基金重点项目1项。现已发表140多篇科研原著、特邀专题评论、特约综述、综述和通讯等,论文总引用次数为2696次,其中他引2416次。近年合作主编英文专著Applying Pharmacogenomics in Therapeutics (在美国出版),应聘为国家卫计委“十三五”暨全国高等医药教材研究会临床医学专业英文版规划教材《药理学》副主编(人民卫生出版社出版)、Molecular Diagnosis & TherapyJournal of Geriatric Cardiology等杂志编委、国内外20多种学术期刊的同行审稿专家。

主要研究方向:
1. 抗血小板药物的药物基因组学与个体化用药研究;
2. 药物代谢与转运及其机制研究;
3. 心血管药物的临床药理学研究。

年发表的SCI论文与专著:

1. Tang HL, Shi WL, Li XG, Zhang T, Zhai SD, Xie HG*. Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: A meta-analysis and trial sequential analysis of 11 randomized controlled trials. The Pharmacogenomics Journal 2015; in press. 

2. Pan YQ, Mi QY, He BS, Zhao SL, Tai T, Xie HG*. The mechanism underlying the induction of hepatic MRP3 expression and function by omeprazole. Biopharmaceutics and Drug Disposition 2015; 36(4):232-244. 

3. Zou JJ, Chen SL, Fan HW, Tang J, He BS, Xie HG*. The CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention. Journal of Cardiovascular Pharmacology 2014; 63(2):178-183. [pubmed]

4.   Zou JJ, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, Lin S, Zhang J, Fan HW, Xie HG*. Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor. PLoS One 2014; 9(1): e84985. 

5.   Wu HL, Duan ZT, Jiang ZD, Cao WJ, Wang ZB, Hu KW, Gao X, Wang SK, He BS, Zhang ZY, Xie HG*. Increased endoplasmic reticulum stress response is involved in clopidogrel-induced apoptosis of gastric epithelial cells. PLoS One 2013; 8(9):e74381. [pubmed]

6.   Zou JJ, Fan HW, Chen SL, Tan J, He BS, Xie HG*. Effect of the ABCC3 -211T/C polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention. Clinical and Experimental Pharmacology and Physiology 2013; 40(8):504-9. [pubmed]

7.   Wu HL, Gao X, Jiang ZD, Duan ZT, Wang SK, He BS, Zhang ZY, Xie HG*. Attenuated expression of the tight junction proteins is involved in clopidogrel-induced gastric injury through p38 MAPK activation. Toxicology 2013; 304(1): 41-48. 

8. Xie HG*, Wang SK, Cao CC, Harpur E. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction. Pharmacology & Therapeutics 2013; 137(1):100-107. 

9. Li Y, Tang HL, Hu YF, Xie HG*. The gain-of-function variant allele CYP2C19*17: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. Journal of Thrombosis & Haemostasis 2012; 10(2):199-206. 

10.   Xie HG*, Zou JJ, Hu ZY, Zhang JJ, Ye F, Chen SL. Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond.  Pharmacology & Therapeutics 2011; 129 (3): 267-89. 

11.   Xie HG. Chapter 11. Pharmacoeconogenomics: A good marriage of pharmacoeconomics and pharmacogenomics. In: Feng X, Xie HG, eds. Applying Pharmacogenomics in Therapeutics. Taylor & Francis Group, CRC Press, 2016; pp. 271-286. (ISBN 978-1-4665-8267-5)

12. Xie HG, Zhang YD. Chapter 22. Pharmacogenomics and Personalized Medicine of the  Antiplatelet Drugs. In: Barh D, Dhawan D, Ganguly NK, eds. Omics for Personalized Medicine. Springer India, New Delhi, India, 2013, pp. 469-506. 


联系方式:
电话:025-5288-7034; E-mail: honggxie@163.com; hongg.xie@gmail.com